CHO Cell Line Development Service - DNA2Pool Service Package

Tech Support Documents
CHO Cell Line Development Service - DNA2Pool Service Package CHO Cell Line Development Service - DNA2Pool Service Package CHO Cell Line Development Service - DNA2Pool Service Package CHO Cell Line Development Service - DNA2Pool Service Package CHO Cell Line Development Service - DNA2Pool Service Package CHO Cell Line Development Service - DNA2Pool Service Package
 

Outsource your CHO cell line development program (partially or entirely) to Sartorius as your extended laboratory bench and trusted drug development partner. Select your service package from DNA2Pool (feasibility | manufacturability assessment), DNA2RCB (complete program up to research cell bank) and DNA2MCB (complete program up to GMP master cell bank).

In 2026, we have upgraded our CLD technology with the launch of our novel genetically engineered CHO host cell line with up to 2-fold and 3-fold increase in titer and cell-specific productivity respectively across different protein molecule types. This host was rationally designed through proteomic profiling and CRISPR-mediated gene editing to deliver a more productive host while maintaining product quality and robust stability.

CLD Workflow
Item No.: 
CHO-CLD-DNA2POOL
*Custom/bulk order quotes are provided within 72 hours of request.
CHO Cell Line Development Service - DNA2Pool Service Package
CHO Cell Line Development Service - DNA2Pool Service Package

Outsource your CHO cell line development program (partially or entirely) to Sartorius as your extended laboratory bench and trusted drug development partner. Select your service package from DNA2Pool (feasibility | manufacturability assessment), DNA2RCB (complete program up to research cell bank) and DNA2MCB (complete program up to GMP master cell bank).

In 2026, we have upgraded our CLD technology with the launch of our novel genetically engineered CHO host cell line with up to 2-fold and 3-fold increase in titer and cell-specific productivity respectively across different protein molecule types. This host was rationally designed through proteomic profiling and CRISPR-mediated gene editing to deliver a more productive host while maintaining product quality and robust stability.

Item No.:
CHO-CLD-DNA2POOL

Overview

Specifications

Choose your CHO Cell Line Development Service

See more products

The purpose of the DNA2Pool service package is to evaluate the expression of your target molecule(s) using our CHO Cell Line Development Service Platform for feasibility and | or manufacturability assessment.

Our standard DNA2Pool approach delivers pool material in 6 weeks* and includes:

  • Gene Synthesis: preparation of the sequence and DNA synthesis, followed by sequence confirmation.
  • Vector Cloning: cloning of genes into Sartorius’ expression vector, followed by sequence confirmation
  • Transfection & Pool Generation: vector transfection, large pool generation, and evaluation of three different construct pools in standard fed-batch cultures.

You have the option to add additional candidates for the same target as needed. We also provide an alternative approach using mini-pools in case you require a pre-defined quality profile for your molecule. Both our large and mini-pool approaches can generate early material for toxicology studies (up to 50 g), ensuring critical quality attributes (CQAs) are comparable to the final clone.

It is important to note that the scope of work described above is not exhaustive. Please request a quote and contact our CHO cell line development experts to discuss how we can design a tailored project to fit your project and | or product requirements.

*For conventional monoclonal antibodies

Applications

  • Application
    Research

General Specifications

  • CLD Service
    Outsourced
  • CLD Workflow
    DNA to Pool
  • Deliverables
    • Pool Material
    • Documentation
  • Drug Type
    • Biosimilars
    • New Biological Entity (NBE)
  • Molecule
    • Conventional mAbs
    • Bi- and Multispecific Antibodies
    • FC-Fusion Proteins
    • Non-Antibody Products